APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dementia Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Dementia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchDementia Drugs Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Dementia Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Dementia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dementia Drugs Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Dementia Drugs Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Dementia Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Dementia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dementia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dementia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Dementia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Dementia Drugs include Janssen Pharmaceuticals, Inc, Eisai, Inc, Teva Pharmaceuticals Industries, Sanofi S.A, Johnson and Johnson, Novartis AG, Eli Lilly and Company, Pfizer Inc and Abbvie Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dementia Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dementia Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dementia Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dementia Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Dementia Drugs Segment by Company

Janssen Pharmaceuticals, Inc

Eisai, Inc

Teva Pharmaceuticals Industries

Sanofi S.A

Johnson and Johnson

Novartis AG

Eli Lilly and Company

Pfizer Inc

Abbvie Inc

AstraZeneca GmbH

Zydus Cadila

Valeant Pharmaceutical International

Merck & Co., Inc

Forest Laboratories, Inc

F. Hoffmann-La Roche

Biogen Pharmaceuticals

Aurobindo Pharma

Apotex inc.

Dementia Drugs Segment by Type

Glutamate Inhibitors

Cholinesterase Inhibitors

MAO Inhibitors

Dementia Drugs Segment by Application

Hospital Pharmacies

Retail Pharmacies

Others

Dementia Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dementia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dementia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dementia Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dementia Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Dementia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Dementia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Dementia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Dementia Drugs Industry Trends Table 2. Dementia Drugs Industry Drivers Table 3. Dementia Drugs Industry Opportunities and Challenges Table 4. Dementia Drugs Industry Restraints Table 5. Global Dementia Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Dementia Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Dementia Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Dementia Drugs Sales Market Share by Manufacturers Table 9. Global Dementia Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Dementia Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Dementia Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Dementia Drugs Manufacturers, Product Type & Application Table 13. Global Dementia Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Dementia Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Glutamate Inhibitors Table 17. Major Manufacturers of Cholinesterase Inhibitors Table 18. Major Manufacturers of MAO Inhibitors Table 19. Global Dementia Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Dementia Drugs Sales by Type (2021-2026) & (k units) Table 21. Global Dementia Drugs Sales by Type (2027-2032) & (k units) Table 22. Global Dementia Drugs Sales Market Share by Type (2021-2026) Table 23. Global Dementia Drugs Sales Market Share by Type (2027-2032) Table 24. Global Dementia Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Dementia Drugs Revenue by Type (2021-2026) & (k units) Table 26. Global Dementia Drugs Revenue by Type (2027-2032) & (k units) Table 27. Global Dementia Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Dementia Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Pharmacies Table 30. Major Manufacturers of Retail Pharmacies Table 31. Major Manufacturers of Others Table 32. Global Dementia Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Dementia Drugs Sales by Application (2021-2026) & (k units) Table 34. Global Dementia Drugs Sales by Application (2027-2032) & (k units) Table 35. Global Dementia Drugs Sales Market Share by Application (2021-2026) Table 36. Global Dementia Drugs Sales Market Share by Application (2027-2032) Table 37. Global Dementia Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Dementia Drugs Revenue by Application (2021-2026) & (k units) Table 39. Global Dementia Drugs Revenue by Application (2027-2032) & (k units) Table 40. Global Dementia Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Dementia Drugs Revenue Market Share by Application (2027-2032) Table 42. Global Dementia Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Dementia Drugs Sales by Region (2021-2026) & (k units) Table 44. Global Dementia Drugs Sales Market Share by Region (2021-2026) Table 45. Global Dementia Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Dementia Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Dementia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Dementia Drugs Sales by Country (2021-2026) & (k units) Table 49. North America Dementia Drugs Sales by Country (2027-2032) & (k units) Table 50. Europe Dementia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Dementia Drugs Sales by Country (2021-2026) & (k units) Table 52. Europe Dementia Drugs Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Dementia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Dementia Drugs Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Dementia Drugs Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Dementia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Dementia Drugs Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Dementia Drugs Sales by Country (2027-2032) & (k units) Table 59. Global Dementia Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Dementia Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Dementia Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Dementia Drugs Revenue Market Share by Region (2021-2026) Table 63. Global Dementia Drugs Revenue Market Share by Region (2027-2032) Table 64. Janssen Pharmaceuticals, Inc Company Information Table 65. Janssen Pharmaceuticals, Inc Business Overview Table 66. Janssen Pharmaceuticals, Inc Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Janssen Pharmaceuticals, Inc Dementia Drugs Product Portfolio Table 68. Janssen Pharmaceuticals, Inc Recent Development Table 69. Eisai, Inc Company Information Table 70. Eisai, Inc Business Overview Table 71. Eisai, Inc Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Eisai, Inc Dementia Drugs Product Portfolio Table 73. Eisai, Inc Recent Development Table 74. Teva Pharmaceuticals Industries Company Information Table 75. Teva Pharmaceuticals Industries Business Overview Table 76. Teva Pharmaceuticals Industries Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Teva Pharmaceuticals Industries Dementia Drugs Product Portfolio Table 78. Teva Pharmaceuticals Industries Recent Development Table 79. Sanofi S.A Company Information Table 80. Sanofi S.A Business Overview Table 81. Sanofi S.A Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Sanofi S.A Dementia Drugs Product Portfolio Table 83. Sanofi S.A Recent Development Table 84. Johnson and Johnson Company Information Table 85. Johnson and Johnson Business Overview Table 86. Johnson and Johnson Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Johnson and Johnson Dementia Drugs Product Portfolio Table 88. Johnson and Johnson Recent Development Table 89. Novartis AG Company Information Table 90. Novartis AG Business Overview Table 91. Novartis AG Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Novartis AG Dementia Drugs Product Portfolio Table 93. Novartis AG Recent Development Table 94. Eli Lilly and Company Company Information Table 95. Eli Lilly and Company Business Overview Table 96. Eli Lilly and Company Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Eli Lilly and Company Dementia Drugs Product Portfolio Table 98. Eli Lilly and Company Recent Development Table 99. Pfizer Inc Company Information Table 100. Pfizer Inc Business Overview Table 101. Pfizer Inc Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Pfizer Inc Dementia Drugs Product Portfolio Table 103. Pfizer Inc Recent Development Table 104. Abbvie Inc Company Information Table 105. Abbvie Inc Business Overview Table 106. Abbvie Inc Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Abbvie Inc Dementia Drugs Product Portfolio Table 108. Abbvie Inc Recent Development Table 109. AstraZeneca GmbH Company Information Table 110. AstraZeneca GmbH Business Overview Table 111. AstraZeneca GmbH Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. AstraZeneca GmbH Dementia Drugs Product Portfolio Table 113. AstraZeneca GmbH Recent Development Table 114. Zydus Cadila Company Information Table 115. Zydus Cadila Business Overview Table 116. Zydus Cadila Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Zydus Cadila Dementia Drugs Product Portfolio Table 118. Zydus Cadila Recent Development Table 119. Valeant Pharmaceutical International Company Information Table 120. Valeant Pharmaceutical International Business Overview Table 121. Valeant Pharmaceutical International Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Valeant Pharmaceutical International Dementia Drugs Product Portfolio Table 123. Valeant Pharmaceutical International Recent Development Table 124. Merck & Co., Inc Company Information Table 125. Merck & Co., Inc Business Overview Table 126. Merck & Co., Inc Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Merck & Co., Inc Dementia Drugs Product Portfolio Table 128. Merck & Co., Inc Recent Development Table 129. Forest Laboratories, Inc Company Information Table 130. Forest Laboratories, Inc Business Overview Table 131. Forest Laboratories, Inc Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Forest Laboratories, Inc Dementia Drugs Product Portfolio Table 133. Forest Laboratories, Inc Recent Development Table 134. F. Hoffmann-La Roche Company Information Table 135. F. Hoffmann-La Roche Business Overview Table 136. F. Hoffmann-La Roche Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. F. Hoffmann-La Roche Dementia Drugs Product Portfolio Table 138. F. Hoffmann-La Roche Recent Development Table 139. Biogen Pharmaceuticals Company Information Table 140. Biogen Pharmaceuticals Business Overview Table 141. Biogen Pharmaceuticals Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Biogen Pharmaceuticals Dementia Drugs Product Portfolio Table 143. Biogen Pharmaceuticals Recent Development Table 144. Aurobindo Pharma Company Information Table 145. Aurobindo Pharma Business Overview Table 146. Aurobindo Pharma Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Aurobindo Pharma Dementia Drugs Product Portfolio Table 148. Aurobindo Pharma Recent Development Table 149. Apotex inc. Company Information Table 150. Apotex inc. Business Overview Table 151. Apotex inc. Dementia Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. Apotex inc. Dementia Drugs Product Portfolio Table 153. Apotex inc. Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Dementia Drugs Distributors List Table 157. Dementia Drugs Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Dementia Drugs Product Image Figure 2. Global Dementia Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dementia Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Dementia Drugs Sales (2021-2032) & (k units) Figure 5. Global Dementia Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Dementia Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Glutamate Inhibitors Image Figure 9. Cholinesterase Inhibitors Image Figure 10. MAO Inhibitors Image Figure 11. Global Dementia Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Dementia Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Dementia Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Dementia Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Dementia Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Dementia Drugs Revenue Market Share by Type (2021-2032) Figure 17. Hospital Pharmacies Image Figure 18. Retail Pharmacies Image Figure 19. Others Image Figure 20. Global Dementia Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Dementia Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Dementia Drugs Sales Market Share by Application (2021-2032) Figure 23. Global Dementia Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Dementia Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Dementia Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Dementia Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Dementia Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Dementia Drugs Sales Market Share by Country (2021-2032) Figure 40. China Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Dementia Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Dementia Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Dementia Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Dementia Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Dementia Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America Dementia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Dementia Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe Dementia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Dementia Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Dementia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Dementia Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Dementia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Dementia Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Dementia Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Glutamate Inhibitors
  • Cholinesterase Inhibitors
  • MAO Inhibitors
Applications
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
Companies covered
  • Janssen Pharmaceuticals, Inc
  • Eisai, Inc
  • Teva Pharmaceuticals Industries
  • Sanofi S.A
  • Johnson and Johnson
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc
  • Abbvie Inc
  • AstraZeneca GmbH
  • Zydus Cadila
  • Valeant Pharmaceutical International
  • Merck & Co., Inc
  • Forest Laboratories, Inc
  • F. Hoffmann-La Roche
  • Biogen Pharmaceuticals
  • Aurobindo Pharma
  • Apotex inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Dementia Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Dementia Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Dementia Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Dementia Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Dementia Drugs Market Dynamics
  1. 2.1 Dementia Drugs Industry Trends
  2. 2.2 Dementia Drugs Industry Drivers
  3. 2.3 Dementia Drugs Industry Opportunities and Challenges
  4. 2.4 Dementia Drugs Industry Restraints
3 Dementia Drugs Market by Manufacturers
  1. 3.1 Global Dementia Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Dementia Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Dementia Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Dementia Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Dementia Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Dementia Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Dementia Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Dementia Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Dementia Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Dementia Drugs Tier 1, Tier 2, and Tier 3
4 Dementia Drugs Market by Type
  1. 4.1 Dementia Drugs Type Introduction
  2. 4.1.1 Glutamate Inhibitors
  3. 4.1.2 Cholinesterase Inhibitors
  4. 4.1.3 MAO Inhibitors
  5. 4.2 Global Dementia Drugs Sales by Type
  6. 4.2.1 Global Dementia Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Dementia Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Dementia Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Dementia Drugs Revenue by Type
  10. 4.3.1 Global Dementia Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Dementia Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Dementia Drugs Revenue Market Share by Type (2021-2032)
5 Dementia Drugs Market by Application
  1. 5.1 Dementia Drugs Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Others
  5. 5.2 Global Dementia Drugs Sales by Application
  6. 5.2.1 Global Dementia Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Dementia Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Dementia Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Dementia Drugs Revenue by Application
  10. 5.3.1 Global Dementia Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Dementia Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Dementia Drugs Revenue Market Share by Application (2021-2032)
6 Global Dementia Drugs Sales by Region
  1. 6.1 Global Dementia Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dementia Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Dementia Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Dementia Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Dementia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Dementia Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Dementia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Dementia Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Dementia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Dementia Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Dementia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Dementia Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Dementia Drugs Revenue by Region
  1. 7.1 Global Dementia Drugs Revenue by Region
  2. 7.1.1 Global Dementia Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Dementia Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Dementia Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Dementia Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Dementia Drugs Revenue (2021-2032)
  8. 7.2.2 North America Dementia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Dementia Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Dementia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Dementia Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Dementia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Dementia Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Dementia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Janssen Pharmaceuticals, Inc
  2. 8.1.1 Janssen Pharmaceuticals, Inc Company Information
  3. 8.1.2 Janssen Pharmaceuticals, Inc Business Overview
  4. 8.1.3 Janssen Pharmaceuticals, Inc Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Janssen Pharmaceuticals, Inc Dementia Drugs Product Portfolio
  6. 8.1.5 Janssen Pharmaceuticals, Inc Recent Developments
  7. 8.2 Eisai, Inc
  8. 8.2.1 Eisai, Inc Company Information
  9. 8.2.2 Eisai, Inc Business Overview
  10. 8.2.3 Eisai, Inc Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eisai, Inc Dementia Drugs Product Portfolio
  12. 8.2.5 Eisai, Inc Recent Developments
  13. 8.3 Teva Pharmaceuticals Industries
  14. 8.3.1 Teva Pharmaceuticals Industries Company Information
  15. 8.3.2 Teva Pharmaceuticals Industries Business Overview
  16. 8.3.3 Teva Pharmaceuticals Industries Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Teva Pharmaceuticals Industries Dementia Drugs Product Portfolio
  18. 8.3.5 Teva Pharmaceuticals Industries Recent Developments
  19. 8.4 Sanofi S.A
  20. 8.4.1 Sanofi S.A Company Information
  21. 8.4.2 Sanofi S.A Business Overview
  22. 8.4.3 Sanofi S.A Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi S.A Dementia Drugs Product Portfolio
  24. 8.4.5 Sanofi S.A Recent Developments
  25. 8.5 Johnson and Johnson
  26. 8.5.1 Johnson and Johnson Company Information
  27. 8.5.2 Johnson and Johnson Business Overview
  28. 8.5.3 Johnson and Johnson Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Johnson and Johnson Dementia Drugs Product Portfolio
  30. 8.5.5 Johnson and Johnson Recent Developments
  31. 8.6 Novartis AG
  32. 8.6.1 Novartis AG Company Information
  33. 8.6.2 Novartis AG Business Overview
  34. 8.6.3 Novartis AG Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis AG Dementia Drugs Product Portfolio
  36. 8.6.5 Novartis AG Recent Developments
  37. 8.7 Eli Lilly and Company
  38. 8.7.1 Eli Lilly and Company Company Information
  39. 8.7.2 Eli Lilly and Company Business Overview
  40. 8.7.3 Eli Lilly and Company Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly and Company Dementia Drugs Product Portfolio
  42. 8.7.5 Eli Lilly and Company Recent Developments
  43. 8.8 Pfizer Inc
  44. 8.8.1 Pfizer Inc Company Information
  45. 8.8.2 Pfizer Inc Business Overview
  46. 8.8.3 Pfizer Inc Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Inc Dementia Drugs Product Portfolio
  48. 8.8.5 Pfizer Inc Recent Developments
  49. 8.9 Abbvie Inc
  50. 8.9.1 Abbvie Inc Company Information
  51. 8.9.2 Abbvie Inc Business Overview
  52. 8.9.3 Abbvie Inc Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Abbvie Inc Dementia Drugs Product Portfolio
  54. 8.9.5 Abbvie Inc Recent Developments
  55. 8.10 AstraZeneca GmbH
  56. 8.10.1 AstraZeneca GmbH Company Information
  57. 8.10.2 AstraZeneca GmbH Business Overview
  58. 8.10.3 AstraZeneca GmbH Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca GmbH Dementia Drugs Product Portfolio
  60. 8.10.5 AstraZeneca GmbH Recent Developments
  61. 8.11 Zydus Cadila
  62. 8.11.1 Zydus Cadila Company Information
  63. 8.11.2 Zydus Cadila Business Overview
  64. 8.11.3 Zydus Cadila Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Zydus Cadila Dementia Drugs Product Portfolio
  66. 8.11.5 Zydus Cadila Recent Developments
  67. 8.12 Valeant Pharmaceutical International
  68. 8.12.1 Valeant Pharmaceutical International Company Information
  69. 8.12.2 Valeant Pharmaceutical International Business Overview
  70. 8.12.3 Valeant Pharmaceutical International Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Valeant Pharmaceutical International Dementia Drugs Product Portfolio
  72. 8.12.5 Valeant Pharmaceutical International Recent Developments
  73. 8.13 Merck & Co., Inc
  74. 8.13.1 Merck & Co., Inc Company Information
  75. 8.13.2 Merck & Co., Inc Business Overview
  76. 8.13.3 Merck & Co., Inc Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Merck & Co., Inc Dementia Drugs Product Portfolio
  78. 8.13.5 Merck & Co., Inc Recent Developments
  79. 8.14 Forest Laboratories, Inc
  80. 8.14.1 Forest Laboratories, Inc Company Information
  81. 8.14.2 Forest Laboratories, Inc Business Overview
  82. 8.14.3 Forest Laboratories, Inc Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Forest Laboratories, Inc Dementia Drugs Product Portfolio
  84. 8.14.5 Forest Laboratories, Inc Recent Developments
  85. 8.15 F. Hoffmann-La Roche
  86. 8.15.1 F. Hoffmann-La Roche Company Information
  87. 8.15.2 F. Hoffmann-La Roche Business Overview
  88. 8.15.3 F. Hoffmann-La Roche Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 F. Hoffmann-La Roche Dementia Drugs Product Portfolio
  90. 8.15.5 F. Hoffmann-La Roche Recent Developments
  91. 8.16 Biogen Pharmaceuticals
  92. 8.16.1 Biogen Pharmaceuticals Company Information
  93. 8.16.2 Biogen Pharmaceuticals Business Overview
  94. 8.16.3 Biogen Pharmaceuticals Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Biogen Pharmaceuticals Dementia Drugs Product Portfolio
  96. 8.16.5 Biogen Pharmaceuticals Recent Developments
  97. 8.17 Aurobindo Pharma
  98. 8.17.1 Aurobindo Pharma Company Information
  99. 8.17.2 Aurobindo Pharma Business Overview
  100. 8.17.3 Aurobindo Pharma Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Aurobindo Pharma Dementia Drugs Product Portfolio
  102. 8.17.5 Aurobindo Pharma Recent Developments
  103. 8.18 Apotex inc.
  104. 8.18.1 Apotex inc. Company Information
  105. 8.18.2 Apotex inc. Business Overview
  106. 8.18.3 Apotex inc. Dementia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Apotex inc. Dementia Drugs Product Portfolio
  108. 8.18.5 Apotex inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dementia Drugs Value Chain Analysis
  2. 9.1.1 Dementia Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dementia Drugs Production Mode & Process
  6. 9.2 Dementia Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dementia Drugs Distributors
  9. 9.2.3 Dementia Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst